Search

Your search keyword '"Bibiana Piqué-Leiva"' showing total 2 results
Start Over Author "Bibiana Piqué-Leiva" Topic breast cancer
2 results on '"Bibiana Piqué-Leiva"'

1. External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort

Author

Tim Rattay, Petra Seibold, Miguel E. Aguado-Barrera, Manuel Altabas, David Azria, Gillian C. Barnett, Renée Bultijnck, Jenny Chang-Claude, Ananya Choudhury, Charlotte E. Coles, Alison M. Dunning, Rebecca M. Elliott, Marie-Pierre Farcy Jacquet, Sara Gutiérrez-Enríquez, Kerstie Johnson, Anusha Müller, Giselle Post, Tiziana Rancati, Victoria Reyes, Barry S. Rosenstein, Dirk De Ruysscher, Maria C. de Santis, Elena Sperk, Hilary Stobart, R. Paul Symonds, Begoña Taboada-Valladares, Ana Vega, Liv Veldeman, Adam J. Webb, Catharine M. West, Riccardo Valdagni, Christopher J. Talbot, REQUITE consortium, Yolande Lievens, Marc van Eijkeren, Piet Ost, Valérie Fonteyne, Christel Monten, Wilfried De Neve, Stephanie Peeters, Karin Haustermans, Caroline Weltens, Gilles Defraene, Maarten Lambrecht, Erik van Limberghen, Erik Briers, Celine Bourgier, Muriel Brengues, Roxana Draghici, Francoise Bons, Thomas Blaschke, Christian Weiß, Irmgard Helmbold, Christian Weißenberger, Petra Stegmaier, Johannes Claßen, Ulrich Giesche, Marie-Luise Sautter-Bihl, Burkhard Neu, Thomas Schnabel, Michael Ehmann, Benjamin Gauter-Fleckenstein, Carsten Herskind, Marlon Veldwijk, Jörg Schäfer, Tommaso Giandini, Marzia Franceschini, Claudia Sangalli, Barbara Avuzzi, Sara Morlino, Laura Lozza, Gabriele Pietro, Elena Delmastro, Elisabetta Garibaldi, Alessandro Cicchetti, Ben Vanneste, Bibiana Piqué-Leiva, Meritxel Molla, Alexandra Giraldo, Monica Ramos, Ramon Lobato-Busto, Paloma Sosa-Fajardo, Laura Torrado Moya, Isabel Dominguez-Rios, Irene Fajardo-Paneque, Patricia Calvo-Crespo, Ana Carballo, Paula Peleteiro, Olivia-Fuentes-Rios, Antonio Gomez-Caamano, Victoria Harrop, Debbie Payne, Manjusha Keni, Samuel Lavers, Simon Wright, Sridhar Thiagarajan, Luis Aznar-Garcia, Kiran Kancherla, Christopher Kent, Subramaniam Vasanthan, Donna Appleton, Monika Kaushik, Frances Kenny, Hazem Khout, Jaroslaw Krupa, Kelly V. Lambert, Simon Pilgrim, Sheila Shokuhi, Kalliope Valassiadou, Ion Bioangiu, Kufre Sampson, Ahmed Osman, Corinne Faivre-Finn, Karen Foweraker, Abigail Pascoe, Claire P. Esler, Tim Ward, Daniel S. Higginson, Richard G. Stock, and Sheryl Green

Subjects
validation, prediction model, early toxicity, radiotherapy, breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Acute skin toxicity is a common and usually transient side-effect of breast radiotherapy although, if sufficiently severe, it can affect breast cosmesis, aftercare costs and the patient's quality-of-life. The aim of this study was to develop predictive models for acute skin toxicity using published risk factors and externally validate the models in patients recruited into the prospective multi-center REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve QUalITy of lifE in cancer survivors) study.Methods: Patient and treatment-related risk factors significantly associated with acute breast radiation toxicity on multivariate analysis were identified in the literature. These predictors were used to develop risk models for acute erythema and acute desquamation (skin loss) in three Radiogenomics Consortium cohorts of patients treated by breast-conserving surgery and whole breast external beam radiotherapy (n = 2,031). The models were externally validated in the REQUITE breast cancer cohort (n = 2,057).Results: The final risk model for acute erythema included BMI, breast size, hypo-fractionation, boost, tamoxifen use and smoking status. This model was validated in REQUITE with moderate discrimination (AUC 0.65), calibration and agreement between predicted and observed toxicity (Brier score 0.17). The risk model for acute desquamation, excluding the predictor tamoxifen use, failed to validate in the REQUITE cohort.Conclusions: While most published prediction research in the field has focused on model development, this study reports successful external validation of a predictive model using clinical risk factors for acute erythema following radiotherapy after breast-conserving surgery. This model retained discriminatory power but will benefit from further re-calibration. A similar model to predict acute desquamation failed to validate in the REQUITE cohort. Future improvements and more accurate predictions are expected through the addition of genetic markers and application of other modeling and machine learning techniques.

Published
2020
Full Text
View/download PDF

2. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Author

Manjusha Keni, Luis Aznar-Garcia, Ben G. L. Vanneste, Miguel E. Aguado-Barrera, Marie-Pierre Farcy-Jacquet, Corinne Faivre-Finn, Marlon R. Veldwijk, Rebecca Elliott, Catharine M L West, Yolande Lievens, Irmgard Helmbold, Ulrich Giesche, Monika Kaushik, Pieter Deseyne, Elena Delmastro, David García-Relancio, Barbara Avuzzi, Marcus Mareel, Timothy H Ward, Marzia Franceschini, Annick Van Greveling, Céline Bourgier, Riccardo Valdagni, Alison M. Dunning, Valérie Fonteyne, Petra Stegmaier, Ana Carballo, Kelly Lambert, Piet Ost, Tom Vercauteren, Christopher Kent, Tim Rattay, Hilary Stobart, Kalliope Valassiadou, Simon Wright, Roxana Draghici, Sheryl Green, F. Duprez, Johannes Claßen, Pietro Gabriele, Kufre Sampson, Patricia Calvo-Crespo, Hazem Khout, V. Reyes, Kerstie Johnson, R. Paul Symonds, Anusha Müller, Laura Torrado-Moya, Ava Golchin, Elhaseen Elhamin, Christian Weiß, Alejandro Seoane-Ramallo, Kiran Kancherla, Ahmed Osman, Irene Fajardo-Paneque, Jörg Schäfer, Hannah Dobbelaere, Soumia Arredouani, Paula Peleteiro, Mónica Ramos-Albiac, Dirk De Ruysscher, Petra Seibold, Manolo Altabas, Claudia Sangalli, Renée Bultijnck, Thiagarajan Sridhar, Marc van Eijkeren, Elena Sperk, Samuel Lavers, Jaroslaw Krupa, A. Giraldo, Martijn Swimberghe, Ana Vega, Christopher J. Talbot, Richard G. Stock, Ion Boiangui, Juan Fernández-Tajes, Claire P. Esler, Sara Gutiérrez-Enríquez, Muriel Brengues, Isabel Dominguez-Rios, Olivia Fuentes-Rios, Daniel S. Higginson, Katrien Vandecasteele, A. Webb, Alessandro Cicchetti, Thomas Blaschke, Maria De Santis, Laura Fachal, Christian Weißenberger, Subramaniam Vasanthan, Bibiana Piqué-Leiva, Laura Lozza, Wilfried De Neve, Maarten Lambrecht, Paloma Sosa-Fajardo, Sheila Shokuhi, Ramón Lobato-Busto, Giselle Post, Carsten Herskind, Frances Kenny, Abigail Pascoe, Belina Rodriguez-Lage, Thomas Schnabel, Donna Appleton, Barry S. Rosenstein, Elisabetta Garibaldi, Christel Monten, Tiziana Rancati, Ananya Choudhury, David Azria, Leen Paelinck, Liv Veldeman, Erik Briers, Begoña Taboada-Valladares, Burkhard Neu, Simon Pilgrim, Jenny Chang-Claude, Antonio Gómez-Caamaño, Gilles Defraene, R Aerts, William Li, Victoria Harrop, S. Morlino, Frank A. Giordano, Debbie Payne, M. Molla, Karen Foweraker, Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and Promovendi ODB

Subjects
Oncology, Male, Lung Neoplasms, medicine.medical_treatment, EUROPEAN-ORGANIZATION, LATE TOXICITY, 030218 nuclear medicine & medical imaging, Cohort Studies, Prostate cancer, 0302 clinical medicine, Breast cancer, QUALITY-OF-LIFE, Medicine and Health Sciences, REPORTED OUTCOMES, Prospective Studies, Prospective cohort study, RISK, Aged, 80 and over, Manchester Cancer Research Centre, Hematology, Middle Aged, Biobank, DATA METAANALYSIS SHOWS, Radiology Nuclear Medicine and imaging, 030220 oncology & carcinogenesis, Female, Lung cancer, Cohort study, Adult, medicine.medical_specialty, Breast Neoplasms, Prediction models, 03 medical and health sciences, Internal medicine, RADIATION-THERAPY, medicine, Humans, Radiology, Nuclear Medicine and imaging, GENOME-WIDE ASSOCIATION, POLYMORPHISMS, Aged, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, Prostatic Neoplasms, medicine.disease, NO ASSOCIATION, Radiation therapy, business, Late radiotherapy side effects, Biomarkers
Abstract

PURPOSE: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. METHODS: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. RESULTS: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). CONCLUSION: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. PATIENT SUMMARY: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity. ispartof: RADIOTHERAPY AND ONCOLOGY vol:138 pages:59-67 ispartof: location:Ireland status: published

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results